News and Trends 11 Apr 2023 PsychoGenics launches eCube AI platform for drug discovery PsychoGenics Inc. has launched eCube, a pharmaco-electroencephalography (pharmacoEEG) platform to support phenotypic drug discovery. The company said that unlike traditional target-based drug discovery, this technique can identify novel treatments with multiple targets. Similar to the company’s AI-enabled, behavior-based platform, SmartCube, eCube harnesses machine learning to identify central nervous system (CNS) penetrant compounds and predict their […] April 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Mar 2023 Iktos raises €15.5M to expand AI drug discovery technologies Iktos, a company specializing in artificial intelligence (AI) for new drug discovery, has closed a €15.5 million ($16.4 million) Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. This financing will enable Iktos to further develop its AI and drug discovery capabilities and expand its existing SaaS software […] March 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by B2B - Breast2Bone 21 Feb 2023 From breast to bone: Refining metastasis drug discovery with a novel organ-on-a-chip device Understanding invasive cancer progression and metastasis formation are among the core open questions in cancer research. However, the limitations of current models lead to high failure rates in drug development. An EU-funded consortium has designed an organ-on-a-chip approach that could deliver new insights. In metastasis, circulating tumor cells spontaneously shed from the primary site to […] February 21, 2023 - 6 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2023 Astex and Cardiff University Medicines Discovery Institute to collaborate on neurodegenerative diseases Astex Pharmaceuticals (UK), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system and The Medicines Discovery Institute, Cardiff University (MDI) have entered into a multi-year, multi-million-pound drug discovery research collaboration, aimed to identify new drugs to treat neurodegenerative diseases. The collaboration […] February 14, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Feb 2023 Icosagen receives €18M loan for R&D and new facility The Estonian biopharma company Icosagen AS has reached an €18 million financing agreement with the European Investment Bank (EIB) backed by the InvestEU program. The funds will strengthen the company’s drug discovery, development and production services. The funds are part of Icosagen’s €40 million investment into increasing its innovative contract research and development capabilities as […] February 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Feb 2023 Possible drug targets from Korean atherosclerosis research Research suggests that the enzyme phosphoenolpyruvate carboxykinase 2 (PCK2) and its gene play a role in the development of vascular injury and atherosclerosis. Atherosclerosis is a deadly disease; research suggests that proliferation of vascular smooth muscle cells (VSMCs) and formation of a neointimal layer along the inner lining of arteries play a major role in […] February 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 1 Feb 2023 Computational chemistry and cancer by Martin Slater, Cresset Discovery Computational chemistry offers a fast and innovative approach to drug discovery and is especially powerful when used in combination with biological testing to provide a complete and reliable picture of a target system. This is perhaps no better illustrated than in Cresset Discovery’s project with University of South Australia, which […] February 1, 2023 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 19 Jan 2023 Interview: Proscia talks about digital pathology Labiotech recently interviewed Nathan Buchbinder, chief product officer at Proscia, about digital pathology. AI has been a hot topic in drug discovery. Can you outline how it’s being applied to pathology data? Sure, it’s always great to start with such an exciting topic! There are two broad applications of AI that I want to highlight. […] January 19, 2023 - 8 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 Collaboration to boost pandemic preparedness, structure-based drug discovery and vaccine design A new Memorandum of Understanding (MoU) to facilitate collaboration in the field of pandemic preparedness and to promote further cooperation between the University of Oxford and Diamond Light Source has been announced. The University of Oxford and Diamond Light Source already have many links but now intend to develop their collaborative work to address multiple […] January 12, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 We DUB this target ‘druggable’ By Sheelagh Frame, CSO at Ubiquigent Modulation of the ubiquitin-proteasome system (UPS) presents a rich source for drug discovery. Recent years have seen the clinical validation of proteolysis-targeting chimeras (PROTACs) unlock the ability to drug the undruggable, by exploiting E3 ligases to mediate targeted protein degradation (TPD), paving the way to tackle exciting new drug […] January 11, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Watch: Interview with IRBM’s Heidi Kingdon Jones The IRBM Group is an innovative research and discovery CRO (contract research organization) working across all aspects of drug discovery and early development. Headquartered in Italy, the company fosters collaborations with organizations from the pharma, biotech, non-profit and academic sectors to accelerate the development of vaccines and medicines. About 250 scientists work at the company’s […] December 20, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2022 Cyclica and SK Chemicals to co-develop novel therapeutics Cyclica Inc. and SK Chemicals Co., Ltd. have announced an AI-driven drug discovery and development partnership to develop therapies across a range of disease areas. Under this collaboration, Cyclica will deploy its proprietary drug discovery platforms to identify novel drug candidates for challenging biological targets across therapeutic areas of mutual interest to both companies. SK […] December 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email